|
Synonyms: 8c10 | BTT-1023 | BTT1023 | r8c10 | SI-3106 | SI-636
Compound class:
Antibody
Comment: Tmolumab is a fully human anti-AOC3 (amine oxidase copper containing 3, VAP1) monoclonal antibody being investigated for its immunomodulatory action.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Protein BLAST analysis reveals 100% matches with peptides claimed in patent US7897149, in particular with the recombinant fully human antibody BTT-1023 named therein [1]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| Timolumab (with research code BTT1023) is being evaluated in Phase 2 clinical trial NCT02239211, for its potential to treat patients with primary sclerosing cholangitis, an uncommon and progressive disease of the bile ducts characterised by inflammation and obliterative fibrosis. Phase 1 studies for RA and psoriasis have been completed (2010/11). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02239211 | A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis | Phase 2 Interventional | University of Birmingham | ||
